Eiger BioPharmaceuticals (EIGR -2%) files an Investigational New Drug (IND) application with the FDA for exendin 9-39 for the potential treatment of post-bariatric hypoglycemia (PBH), a rare and chronic disorder with no approved treatment.
Exendin 9-39, exclusively licensed from Stanford University, is a 31-amino acid peptide that selectively targets and blocks GLP-1 receptors, normalizing insulin secretion by the pancreas and reducing PBH.
The company is investigating a subcutaneous formulation. Interim data from a multiple-ascending dose study in PBH patients will be presented at Eiger's Analyst/Key Opinion Leader event on December 9.
The company says there are 150K - 200K bariatric surgeries performed annually in the U.S. and another 100K/year in Europe. PBH occurs in ~30K Americans and 25K people in the EU.